Free Trial

Outlook Therapeutics (OTLK) Stock Forecast & Price Target

Outlook Therapeutics logo
$6.51 +0.16 (+2.52%)
(As of 11/6/2024 ET)

Outlook Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
7

Based on 7 Wall Street analysts who have issued ratings for Outlook Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 7 have given a buy rating for OTLK.

Consensus Price Target

$48.20
640.40% Upside
According to the 7 analysts' twelve-month price targets for Outlook Therapeutics, the average price target is $48.20. The highest price target for OTLK is $100.00, while the lowest price target for OTLK is $30.00. The average price target represents a forecasted upside of 640.40% from the current price of $6.51.
Get the Latest News and Ratings for OTLK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Outlook Therapeutics and its competitors.

Sign Up

OTLK Analyst Ratings Over Time

TypeCurrent Forecast
11/7/23 to 11/6/24
1 Month Ago
10/8/23 to 10/7/24
3 Months Ago
8/9/23 to 8/8/24
1 Year Ago
11/7/22 to 11/7/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
1 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$48.20$48.20$46.43$92.00
Forecasted Upside640.40% Upside843.25% Upside525.67% Upside807.30% Upside
Consensus Rating
Buy
Buy
Moderate Buy
Hold

OTLK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

OTLK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Outlook Therapeutics Stock vs. The Competition

TypeOutlook TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.79
2.50
Consensus RatingBuyModerate BuyHold
Predicted Upside640.40% Upside16,941.80% Upside7.32% Upside
News Sentiment Rating
Positive News

See Recent OTLK News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/18/2024BTIG Research
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00+874.66%
9/3/2024Ascendiant Capital Markets
2 of 5 stars
 Lower TargetBuy ➝ Buy$35.00 ➝ $33.00+348.98%
8/16/2024Chardan Capital
2 of 5 stars
D. Gataulin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$53.00 ➝ $53.00+570.89%
8/15/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00+308.72%
2/16/2024Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Chiang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
1/25/2024Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Dolliver
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$31.40+292.50%
1/25/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$40.00+400.00%
8/30/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Kluska
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$90.00 ➝ $20.00+340.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:49 AM ET.


OTLK Forecast - Frequently Asked Questions

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Outlook Therapeutics is $48.20, with a high forecast of $100.00 and a low forecast of $30.00.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OTLK shares.

According to analysts, Outlook Therapeutics's stock has a predicted upside of 640.40% based on their 12-month stock forecasts.

Outlook Therapeutics has been rated by research analysts at Ascendiant Capital Markets, BTIG Research, Chardan Capital, and HC Wainwright in the past 90 days.

Analysts like Outlook Therapeutics more than other "medical" companies. The consensus rating for Outlook Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how OTLK compares to other companies.


This page (NASDAQ:OTLK) was last updated on 11/6/2024 by MarketBeat.com Staff
From Our Partners